December 3, 2019 / 11:36 PM / 10 days ago

BRIEF-FDA Approves Genentech's Tecentriq Plus Chemotherapy (Abraxane And Carboplatin) For Initial Treatment Of Metastatic Non-Squamous Non-Small Cell Lung Cancer

Dec 3 (Reuters) - Roche Holding AG:

* FDA APPROVES GENENTECH’S TECENTRIQ PLUS CHEMOTHERAPY (ABRAXANE AND CARBOPLATIN) FOR THE INITIAL TREATMENT OF METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

* GENENTECH - APPROVAL BASED ON PHASE III IMPOWER130 STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below